Clonal Architecture in Mesothelioma is Prognostic and Shapes the Tumour Microenvironment
Overview
Authors
Affiliations
Malignant Pleural Mesothelioma (MPM) is typically diagnosed 20-50 years after exposure to asbestos and evolves along an unknown evolutionary trajectory. To elucidate this path, we conducted multi-regional exome sequencing of 90 tumour samples from 22 MPMs acquired at surgery. Here we show that exomic intratumour heterogeneity varies widely across the cohort. Phylogenetic tree topology ranges from linear to highly branched, reflecting a steep gradient of genomic instability. Using transfer learning, we detect repeated evolution, resolving 5 clusters that are prognostic, with temporally ordered clonal drivers. BAP1/-3p21 and FBXW7/-chr4 events are always early clonal. In contrast, NF2/-22q events, leading to Hippo pathway inactivation are predominantly late clonal, positively selected, and when subclonal, exhibit parallel evolution indicating an evolutionary constraint. Very late somatic alteration of NF2/22q occurred in one patient 12 years after surgery. Clonal architecture and evolutionary clusters dictate MPM inflammation and immune evasion. These results reveal potentially drugable evolutionary bottlenecking in MPM, and an impact of clonal architecture on shaping the immune landscape, with potential to dictate the clinical response to immune checkpoint inhibition.
Mesothelioma cell heterogeneity identified by single cell RNA sequencing.
Wu L, Wang Z, Zia A, Kelley S, de Perrot M Sci Rep. 2025; 15(1):8725.
PMID: 40082554 PMC: 11906801. DOI: 10.1038/s41598-025-92542-3.
Torricelli F, Spada F, Bishop C, Todd K, Nonaka D, Petrov N J Transl Med. 2025; 23(1):208.
PMID: 39980060 PMC: 11844119. DOI: 10.1186/s12967-025-06193-z.
Editorial: Asbestos and disease genomics: is mesothelioma a genomic paradigm?.
Jaurand M, Murphy F, Felley-Bosco E Front Toxicol. 2025; 6():1536344.
PMID: 39831064 PMC: 11739162. DOI: 10.3389/ftox.2024.1536344.
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.
Zhang M, Bzura A, Baitei E, Zhou Z, Spicer J, Poile C Nat Commun. 2024; 15(1):7187.
PMID: 39168966 PMC: 11339264. DOI: 10.1038/s41467-024-49842-5.
Mesothelioma: molecular pathology and biomarkers.
Hung Y Pathologie (Heidelb). 2024; 45(5):316-323.
PMID: 39110166 DOI: 10.1007/s00292-024-01344-3.